Participation of central imidazoline binding sites in antinociceptive effect of ethanol and nicotine in rats

Fundamental and Clinical Pharmacology

Volumn 28, Issue 3, 2014, Pages 284-293

  Aglawe, Manish Manohar ^a   Taksande, Brijesh Gulabrao ^a   Kuldhariya, Sharvari Shambabu ^a   Chopde, Chandrabhan Tukaram ^a   Umekar, Milind Janrao ^a   Kotagale, Nandkishor Ramdas ^a  

^a New Kamptee   (India)

Author keywords

Antinociception; Ethanol; Imidazoline Receptors; Nicotine

Indexed keywords

ALCOHOL; ANALGESIC AGENT; IMIDAZOLINE RECEPTOR; LIGAND; NICOTINE;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BRAIN; DOSE RESPONSE; DRUG EFFECTS; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; METABOLISM; PAIN; PAIN MEASUREMENT; SPRAGUE DAWLEY RAT; SUBSTANCE-RELATED DISORDERS;

ANALGESICS; ANIMALS; BINDING SITES; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; IMIDAZOLINE RECEPTORS; INJECTIONS, INTRAVENTRICULAR; LIGANDS; MALE; NICOTINE; PAIN; PAIN MEASUREMENT; RATS, SPRAGUE-DAWLEY; SUBSTANCE-RELATED DISORDERS;

EID: 84899117719     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12034     Document Type: Article

References (73)

1. Olsen J., Sabreo S., Fasting U. Interaction of alcohol and tobacco as risk factors in cancer of the laryngeal region. J. Epidemiol. Community Health (1985) 39 165-168.
2. Johnson K.A., Jennison K.M. The drinking-smoking syndrome and social context. Int. J. Addict. (1992) 27 749-792.
3. Castellsague X., Munoz N., Stefani D.E., Victoria C.G., Quintana M.J. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of oesophageal cancer in men and women. Int. J. Cancer (1999) 82 657-664.
4. Yoshida K., Engel J., Liljequist S. The effect of chronic ethanol administration of high affinity 3H-nicotinic binding in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. (1982) 321 74-76.
5. Signs S.A., Schechter M.D. Nicotine-induced potentiation of ethanol discrimination. Pharmacol. Biochem. Behav. (1986) 24 769-771.
6. Booker T.K., Collins A.C. Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions. Alcohol (1997) 14 131-140.
7. Penland S., Hoplight B., Obernier J., Crews F.T. Effects of nicotine on ethanol dependence and brain damage. Alcohol (2001) 24 45-54.
8. Howard L.A., Ahluwalia J.S., Lin S.K., Sellers E.M., Tyndale R.F. CYP2E1_1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics (2003) 13 321-328.
9. Howard L.A., Miksys S., Hoffmann E., Mash D., Tyndale R.F. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br. J. Pharmacol. (2003) 138 1376-1386.
10. Rose J.E., Brauer L.H., Behm F.M., Cramblett M., Calkins K., Lawhon D. Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob. Res. (2004) 6 133-144.
11. Korkosz A., Zatorski P., Taracha E., Plaznik A., Kostowski W., Bienkowski P. Ethanol blocks nicotine-induced seizures in mice: comparison with midazolam and baclofen. Alcohol (2006) 40 151-157.
12. Korkosz A., Zatorski P., Taracha E., Plaznik A., Kostowski W., Bienkowski P. Effects of ethanol on nicotine-induced conditioned place preference in C57BL/6J mice. Prog. Neuropsychopharmacol. Biol. Psychiatry (2006) 30 1283-1290.
13. Korkosz A., Scinska A., Taracha E. et al. Nicotine-induced conditioned taste aversion in the rat: effects of ethanol. Eur. J. Pharmacol. (2006) 537 99-105.
14. Parnell S.E., West J.R., Chen W.J. Nicotine decreases blood alcohol concentrations in adult rats: a phenomenon potentially related to gastric function. Alcohol. Clin. Exp. Res. (2006) 30 1408-1413.
15. King A., McNamara P., Conrad M., Cao D. Alcohol-induced increases in smoking behavior for nicotinized and denicotinized cigarettes in men and women. Psychopharmacology (2009) 207 107-117.
16. Ribeiro-Carvalho A., Lima C.S., Medeiros A.H. et al. Combined exposure to nicotine and ethanol in adolescent mice: effects on the central cholinergic systems during short and long term withdrawal. Neuroscience (2009) 162 1174-1186.
17. Connor J.P., Young R.M., Lawford B.R., Saunders J.B., Ritchie T.L., Noble E.P. Heavy nicotine and alcohol use in alcohol dependence is associated with D2 dopamine receptor (DRD2) polymorphism. Addict. Behav. (2006) 32 310-319.
18. Volk H.E., Scherrer J.F., Bucholz K.K. et al. Evidence for specificity of transmission of alcohol and nicotine dependence in an offspring of twins design. Drug Alcohol Depend. (2006) 87 225-232.
19. Le D., Li Z., Funk D., Shram M., Li T.K., Shaham Y. Increased vulnerability to nicotine self-administration and relapse in alcohol-naive offspring of rats selectively bred for high alcohol intake. J. Neurosci. (2006) 26 1872-1879.
20. Rezvani A.H., Levin E.D. Nicotine-alcohol interactions and cognitive function in rats. Pharmacol. Biochem. Behav. (2002) 72 865-872.
21. Al-Rajaie S., Dar M.S. Behavioral interaction between nicotinic and ethanol: possible modulation by mouse cerebellar glutamate. Alcohol. Clin. Exp. Res. (2006) 30 1223-1233.
22. Al-Rajaie S., Dar M.S. Antagonism of ethanol ataxia by intracerebellar nicotine: possible modulation by mouse cerebellar nitric oxide and cGMP. Brain Res. Bull. (2006) 69 187-196.
23. Ceballos N.A., Tivis R., Lawton-Craddock A., Nixond S.J. Nicotine and cognitive efficiency in alcoholics and elicit stimulant abusers: implication of smoking cessation for substance users in treatment. Subst. Use Misuse (2006) 41 265-268.
24. Tizabi Y., Copeland R.L. Jr, Louis V.A., Taylor R.E. Effects of combined systemic alcohol and central nicotine administration into VTA on dopamine release in the nucleus accumbens. Alcohol. Clin. Exp. Res. (2002) 26 394-399.
25. Tizabi Y., Manaye K.F., Smoot D.T., Taylor R.E. Nicotine inhibits ethanol-induced toxicity in cultured cerebral cortical cells. Neurotox. Res. (2004) 6 311-316.
26. Cutter H.S., O'Farell T.J. Experience with alcohol and the endogenous opioid system in ethanol analgesia. Addict. Behav. (1987) 12 331-343.
27. Woodrow K.M., Eltherington L.G. Feeling no pain: alcohol as an analgesic. Pain (1988) 32 159-163.
28. Boada J., Feria M., Sanz E. Inhibitory effect of naloxone on ethanol induced antinociception in mice. Pharmacol. Res. Commun. (1981) 13 673-678.
29. Fertig J.B., Pomerleau O.F., Sanders B. Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addict. Behav. (1986) 11 239-248.
30. Pomerleau O.F., Turk D.C., Fertig J.B. The effects of cigarette smoking on pain and anxiety. Addict. Behav. (1984) 9 265-271.
31. Phan D.V., Doda M., Bite A., Gyorgy L. Antinociceptive activity of nicotine. Acta Physiol. Acad. Sci. (1973) 44 85-93.
32. Damaj M.I., Welech S.P., Martin B.R. Involvement of calcium and L-type channels in nicotine-induced antinociception. J. Pharmacol. Exp. Ther. (1993) 266 1330-1338.
33. Khan I.M., Buerkle H., Taylor P., Yaksh T.L. Nociceptive and antinociceptive responses to intrathecally administered nicotinic agonists. Neuropharmacology (1998) 37 1515-1525.
34. Simons C.T., Cuellar J.M., Moore J.A. et al. Nicotinic receptor involvement in antinociception induced by exposure to cigarette smoke. J. Neurosci. (2005) 26 1872-1879.
35. Vincler M. Neuronal nicotinic receptors as targets for novel analgesics. Expert Opin. Investig. Drugs (2005) 14 1191-1198.
36. Franklin K.B.J. Analgesia and the neural substrate of reward. Neurosci. Biobehav. Rev. (1989) 13 149-154.
37. Franklin K.B.J. Analgesia and abuse potential: an accidental association or a common substrate? Pharmacol. Biochem. Behav. (1998) 59 993-1002.
38. Uzbay I.T., Yesilyurt O., Celik T., Ergun H., Isimer A. Effects of agmatine on ethanol withdrawal syndrome in rats. Behav. Brain Res. (2000) 107 153-159.
39. Gentili F., Cardinaletti C., Carrieri A. et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur. J. Pharmacol. (2006) 553 73-81.
40. Lewis B., Wellmann K., Barron S. Agmatine reduces balance deficits in a rat model of third trimester binge-like alcohol exposure. Pharmacol. Biochem. Behav. (2007) 88 114-121.
41. Ruggiero D.A., Regunathan S., Wang H., Milner T.A., Reis D.J. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. (1998) 780 270-293.
42. Michel M.C., Insel P.A. Are there multiple imidazoline binding sites? Trends Pharmacol. Sci. (1989) 10 342-344.
43. Michel M.C., Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol. Sci. (1992) 13 369-370.
44. Parini A., Moudanos C.G., Pizzinat N., Lanier S.M. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. (1996) 17 13-16.
45. Eglen R.M., Hudson A.L., Kendall D.A. et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. (1998) 19 381-390.
46. De Vos H., Bricca G., De Keyser J., De Backer J.P., Bousquet P., Vauquelin G. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience (1994) 59 589-598.
47. Tesson F., Prip-Buus C., Lemoine A., Pegorier J.P., Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. J. Biol. Chem. (1991) 266 155-160.
48. Raddatz R., Savic S.L., Bakthavachalam V. et al. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J. Pharmacol. Exp. Ther. (2000) 292 1135-1145.
49. Kotagale N.R., Taksande B.G., Gahane A.Y., Ugale R.R., Chopde C.T. Repeated agmatine treatment attenuates nicotine sensitization in mice: modulation by alpha2-adrenoceptors. Behav. Brain Res. (2010) 213 161-174.
50. Taksande B.G., Kotagale N.R., Patel M.R., Shelkar G.P., Ugale R.R., Chopde C.T. Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats. Eur. J. Pharmacol. (2010) 637 89-101.
51. Paxinos G., Watson C. The rat brain in stereotaxic co-ordinates, Elsevier Academic Press, Amsterdam, 2005.
52. Kamei J., Sodeyama M., Tsuda M., Suzuki T., Nagase H. Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice. Life Sci. (1997) 60 333-337.
53. Kamei J., Zushida K. Effect of mexiletine on thermal allodynia and hyperalgesia in diabetic mice. Jpn. J. Pharmacol. (2000) 84 89-92.
54. Campbel V.C., Taylor R.E., Tizabi Y. Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception. Alcohol. Clin. Exp. Res. (2007) 31 1435-1440.
55. Campbel V.C., Taylor R.E., Tizabi Y. Antinociceptive effect of alcohol and nicotine: involvement of the opioid system. Brain Res. (2006) 1097 71-77.
56. Meyerhoff D.J., Tizabi Y., Staley J.K., Durazzo T.C., Glass J.M., Nixon S.J. Smoking comorbidity in alcoholism: neurobiological and neurocognitive consequences. Alcohol. Clin. Exp. Res. (2006) 30 253-264.
57. Ruiz-Durantez E., Torrecilla M., Pineda J., Ugedo L. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. Br. J. Pharmacol. (2003) 138 494-500.
58. Head G.A., Mayorov D.N. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc. Hematol. Agents Med. Chem. (2006) 4 17-32.
59. Li J.X., Zhang Y. Imidazoline I2 receptors: target for new analgesics? Eur. J. Pharmacol. (2011) 658 49-56.
60. Rommelspacher H., May T., Susilo R. Beta-carbolines and tetrahydroisoquinolines: detection and function in mammals. Planta Med. (1991) 57 S85-S92.
61. Rommelspacher H., Dufeu P., Schmidt L.G. Harman and norharman in alcoholism: correlations with psychopathology and long-term changes. Alcohol. Clin. Exp. Res. (1996) 20 3-8.
62. Mao L., Abdel-Rahman A.A. Synergistic behavioral interaction between ethanol and clonidine in rats: role of alpha-2 adrenoceptors. J. Pharmacol. Exp. Ther. (1996) 279 443-449.
63. Spies C.D., Dubisz N., Neumann T. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma. Results of a prospective randomised trial. Crit. Care Med. (1996) 24 414-422.
64. Dobrydnjov I., Axelsson K., Berggren L., Samarutel J., Holmstrom B. Intrathecal and oral clonidine as prophylaxis for postoperative alcohol withdrawal syndrome: a randomized double-blinded study. Anesth. Analg. (2004) 98 738-744.
65. Zaniewska M., McCreary A.C., Sezer G., Przegalinski E., Filip M. Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol. Rep. (2008) 60 645-654.
66. Semenova S., Markou A. The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur. Neuropsychopharmacol. (2010) 20 731-746.
67. Diaz A., Mayet S., Dickenson A.H. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur. J. Pharmacol. (1997) 333 9-15.
68. Yesilyurt O., Uzbay I.T. Agmatine potentiates the analgesic effect of morphine by an alpha(2)-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacol. J. (2001) 25 98-103.
69. Aricioglu F., Korcegez E., Ozyalcin S. Effect of harmane on mononeuropathic pain in rats. Ann. N. Y. Acad. Sci. (2003) 1009 180-184.
70. Fairbanks C.A., Posthumus I.J., Kitto K.F., Stone L.S., Wilcox G.L. Monoxidine, a selective imidazoline/alpha2 adrenergic receptor agonist, synergizes with morphine and deltorphin 2 to inhibit substance P- induced behaviour in mice. Pain (2000) 84 13-20.
71. Yang X.C., Reis D.J. Agmatine selectively blocks the NMDA subclass of glutamate receptor channels in cultured mouse hippocampal neurons. J. Pharmacol. Exp. Ther. (1999) 288 544-549.
72. Olmos G., DeGregorio-Rocasolano N., Paz Regalado M., Gasull T., Assumpcio Boronat M., Trullas R. Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br. J. Pharmacol. (1999) 127 1317-1326.
73. Komissarov I.V., Abramets I.I. Characteristics of GABA-potentiating effect of harmane. Biull. Eksp. Biol. Med. (1982) 94 61-63.